close
MENU
Hunter’s Corner
5 mins to read

Market view of Pacific Edge still rose-tinted

ANALYSIS: Despite the company’s qualities, investors are expecting a lot.

The biotech’s shareholders have long loved the Pacific Edge story.

Tim Hunter Fri, 28 Apr 2023

On the principle that a stopped clock can at least tell the right time twice a day, we can be confident the sharemarket has at some point in the last few years offered a reasonable valuation of biotech company Pacific Edge.

In March 2020 the shares were worth 7c, valuing the company at $48.3

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Tim Hunter Fri, 28 Apr 2023
Contact the Writer: thunter@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Market view of Pacific Edge still rose-tinted
Hunter’s Corner,
98796
true